Chronic wounds, including diabetic ulcers, pressure ulcers, venous ulcers, and arterial insufficiency ulcers, are both difficult and expensive to treat. Conventional wound care may sometimes lead to suboptimal wound healing and significant morbidity and mortality for patients. The use of skin substitutes provides an alternative therapy showing superior efficacy and, in some cases, similar cost-effectiveness compared to traditional treatments. This review discusses the different types of currently available commercial skin substitutes for use in chronic wounds as well as the paucity of strong evidence supporting their use. It then delves into the limitations of these skin substitutes and examines the most recent research targeting these limitations.
FrykbergRGBanksJ. Challenges in the treatment of chronic wounds. Adv Wound Care. 2015;4:560-582.
8.
FarsaeiSKhaliliHFarboudESKhazaeipourZ. Sildenafil in the treatment of pressure ulcer: a randomised clinical trial. Int Wound J. 2015;12:111-117.
9.
GürsoyKOruçMKankayaY. Effect of topically applied sildenafil citrate on wound healing: experimental study. Bosnian J Basic Med Sci. 2014;14:125-131.
10.
ArslantasRArslantasMK. Adverse effect of sildenafil on healing ischemic wounds: results of an in vivo study. Ostomy Wound Manage. 2015;61:32-37.
11.
LangerARogowskiW. Systematic review of economic evaluations of human cell-derived wound care products for the treatment of venous leg and diabetic foot ulcers. BMC Health Serv Res. 2009;9:1-14.
12.
MacNeilS. Progress and opportunities for tissue-engineered skin. Nature. 2007;445:874.
13.
CaleyMPMartinsVLCO’TooleEA. Metalloproteinases and wound healing. Adv Wound Care. 2015;4:225-234.
14.
BrigidoSABocSFLopezRC. Effective management of major lower extremity wounds using an acellular regenerative tissue matrix: a pilot study. Orthopedics. 2004;27:S145-S149.
15.
BrigidoSA. The use of an acellular dermal regenerative tissue matrix in the treatment of lower extremity wounds: a prospective 16-week pilot study. Int Wound J. 2006;3:181-187.
16.
ReyzelmanACrewsRTMooreJC. Clinical effectiveness of an acellular dermal regenerative tissue matrix compared to standard wound management in healing diabetic foot ulcers: a prospective, randomised, multicentre study. Int Wound J. 2009;6:196-208.
17.
ReyzelmanAMBazarovI. Human acellular dermal wound matrix for treatment of DFU: literature review and analysis. J Wound Care. 2015;128:129-134.
18.
Lev-TovHLiC-SDahleSIsseroffRR. Cellular versus acellular matrix devices in treatment of diabetic foot ulcers: study protocol for a comparative efficacy randomized controlled trial. Trials. 2013;14:8.
19.
NicholasMNJeschkeMGAmini-NikS. Methodologies in creating skin substitutes [published online May 6, 2016]. Cell Mol Life Sci.
20.
NegronLLunSMayBC. Ovine forestomach matrix biomaterial is a broad spectrum inhibitor of matrix metalloproteinases and neutrophil elastase. Int Wound J. 2014;11:392-397.
21.
DriverVRLaveryLAReyzelmanAM. A clinical trial of Integra Template for diabetic foot ulcer treatment. Wound Repair Regen. 2015;23:891-900.
22.
VoigtJDriverVR. Hyaluronic acid derivatives and their healing effect on burns, epithelial surgical wounds, and chronic wounds: a systematic review and meta-analysis of randomized controlled trials. Wound Repair Regen. 2012;20:317-331.
23.
CaravaggiCGrigolettoFScuderiN. Wound bed preparation with a dermal substitute (Hyalomatrix® PA) facilitates re-epithelialization and healing: results of a multicenter, prospective, observational study on complex chronic ulcers (The FAST Study). Wounds. 2011;23:228-235.
24.
NolteSVXuWRennekampffHORodemannHP. Diversity of fibroblasts—a review on implications for skin tissue engineering. Cells Tissues Organs. 2008;187:165-176.
25.
NoordenbosJDoreCHansbroughJF. Safety and efficacy of TransCyte for the treatment of partial-thickness burns. J Burn Care Rehabil. 1999;20:275-281.
26.
HartCELoewen-RodriguezALessemJ. Dermagraft: use in the treatment of chronic wounds. Adv Wound Care. 2012;1:138-141.
27.
MarstonWAHanftJNorwoodPPollakR. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers: results of a prospective randomized trial. Diabetes Care. 2003;26:1701-1705.
28.
NiknejadHPeiroviHJorjaniM. Properties of the amniotic membrane for potential use in tissue engineering. Eur Cells Mater. 2008;15:88-99.
29.
SerenaTECarterMJLeLTSaboMJDiMarcoDT. A multicenter, randomized, controlled clinical trial evaluating the use of dehydrated human amnion/chorion membrane allografts and multilayer compression therapy vs. multilayer compression therapy alone in the treatment of venous leg ulcers. Wound Repair Regen. 2014;22:688-693.
30.
ZelenCMSerenaTEGouldL. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13:272-282.
31.
GhaharyAGhaffariA. Role of keratinocyte-fibroblast cross-talk in development of hypertrophic scar. Wound Repair Regen. 2007;15(suppl 1):S46-S53.
32.
WojtowiczAMOliveiraSCarlsonMW. The importance of both fibroblasts and keratinocytes in a bilayered living cellular construct used in wound healing. Wound Repair Regen. 2014;22:246-255.
33.
ZaulyanovLKirsnerRS. A review of a bi-layered living cell treatment (Apligraf®) in the treatment of venous leg ulcers and diabetic foot ulcers. Clin Intervent Aging. 2007;2:93-98.
34.
DiDomenicoLLandsmanAREmchKJLandsmanA. A prospective comparison of diabetic foot ulcers treated with either a cryopreserved skin allograft or a bioengineered skin substitute. Wounds. 2011;23:184-189.
35.
SandersLLandsmanASLandsmanA. A prospective, multicenter, randomized, controlled clinical trial comparing a bioengineered skin substitute to a human skin allograft. Ostomy Wound Manage. 2014;60:26-38.
36.
SnyderDLSullivanNKMS. Skin Substitutes for Treating Chronic Wounds. Rockville, MD: Agency for Healthcare Research and Quality; 2012.
37.
MotoleseAVignatiFBrambillaRCeratiMPassiA. Interaction between a regenerative matrix and wound bed in nonhealing ulcers: results with 16 cases. BioMed Res Int. 2013;2013:849321.
38.
KimmelHRahnMGilbertTW. The clinical effectiveness in wound healing with extracellular matrix derived from porcine urinary bladder matrix: a case series on severe chronic wounds. J Am Coll Cert Wound Special. 2010;2:55-59.
39.
KavrosSJDutraTGonzalez-CruzR. The use of PriMatrix, a fetal bovine acellular dermal matrix, in healing chronic diabetic foot ulcers: a prospective multicenter study. Adv Skin Wound Care. 2014;27:356-362.
40.
LidenBAMayBC. Clinical outcomes following the use of ovine forestomach matrix (endoform dermal template) to treat chronic wounds. Adv Skin Wound Care. 2013;26:164-167.
41.
LeLCarterMJKellerJLiWW. Treatment of chronic diabetic lower extremity ulcers with advanced therapies: a prospective, randomised, controlled, multi-centre comparative study examining clinical efficacy and cost. Int Wound J. 2016;13(2):272-282.
42.
ZelenCMGouldL. A prospective, randomised, controlled, multi-centre comparative effectiveness study of healing using dehydrated human amnion/chorion membrane allograft, bioengineered skin substitute or standard of care for treatment of chronic lower extremity diabetic ulcers. Int Wound J. 2015;12:724-732.
43.
WongVWRustadKCGalvezMG. Engineered pullulan-collagen composite dermal hydrogels improve early cutaneous wound healing. Tissue Eng Part A. 2011;17:631-644.
NicolettiGBrentaFBleveM. Long-term in vivo assessment of bioengineered skin substitutes: a clinical study. J Tissue Eng Regen Med. 2015;9:460-468.
50.
HachiyaASriwiriyanontPKaihoE. An in vivo mouse model of human skin substitute containing spontaneously sorted melanocytes demonstrates physiological changes after UVB irradiation. J Invest Dermatol. 2005;125:364-372.
51.
MoiemenNYarrowJHodgsonE. Long-term clinical and histological analysis of Integra dermal regeneration template. Plast Reconstruct Surg. 2011;127:1149-1154.
52.
ItoMCotsarelisG. Is the hair follicle necessary for normal wound healing?J Invest Dermatol. 2008;128:1059-1061.
53.
RittiéLSachsDLOrringerJSVoorheesJJFisherGJ. Eccrine sweat glands are major contributors to reepithelialization of human wounds. Am J Pathol. 2013;182:163-171.
54.
SriwiriyanontPLynchKAMaierEA. Morphogenesis of chimeric hair follicles in engineered skin substitutes with human keratinocytes and murine dermal papilla cells. Exp Dermatol. 2012;21:783-785.
55.
SriwiriyanontPLynchKAMcFarlandKLSuppDMBoyceST. Characterization of hair follicle development in engineered skin substitutes. PLoS One. 2013;8:e65664.
56.
HuangSXuYWuCShaDFuX. In vitro constitution and in vivo implantation of engineered skin constructs with sweat glands. Biomaterials. 2010;31:5520-5525.
57.
HsuY-CLiLFuchsE. Emerging interactions between skin stem cells and their niches. Nat Med. 2014;20:847-856.
58.
ChiaHNWuBM. Recent advances in 3D printing of biomaterials. J Biol Eng. 2015;9:4.
59.
KochLKuhnSSorgH. Laser printing of skin cells and human stem cells. Tissue Eng Part C Methods. 2010;16:847-854.
60.
MichaelSSorgHPeckCT. Tissue engineered skin substitutes created by laser-assisted bioprinting form skin-like structures in the dorsal skin fold chamber in mice. PLoS One. 2013;8:e57741.
LengLBaQAmini-NikSJeschkeMGuentherA. “Skin Printer: Microfluidic Approach for Skin Regeneration and Wound Dressing” US Prov. Patent Application 61817860, April 302013.
RomanelliMDiniVBertoneMS. Randomized comparison of OASIS wound matrix versus moist wound dressing in the treatment of difficult-to-heal wounds of mixed arterial/venous etiology. Adv Skin Wound Care. 2010;23:34-38.
65.
MostowENHarawayGDDalsingMHoddeJPKingD. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 41:837-843.
66.
NiezgodaJAVan GilsCCFrykbergRGHoddeJP. Randomized clinical trial comparing OASIS Wound Matrix to Regranex Gel for diabetic ulcers. Adv Skin Wound Care. 2005;18:258-266.
67.
BaldurssonBTKjartanssonHKonrádsdóttirF. Healing rate and autoimmune safety of full-thickness wounds treated with fish skin acellular dermal matrix versus porcine small-intestine submucosa: a noninferiority study. Int J Lower Extremity Wounds. 2015;14:37-43.
68.
LandsmanARoukisTSDeFronzoDJ. Living cells or collagen matrix: which is more beneficial in the treatment of diabetic foot ulcers?Wounds. 2008;20:111-116.
69.
RomanelliMDiniVBertoneMBarbaneraSBrilliC. OASIS wound matrix versus Hyaloskin in the treatment of difficult-to-heal wounds of mixed arterial/venous aetiology. Int Wound J. 2007;4:3-7.
70.
VinFTeotLMeaumeS. The healing properties of Promogran in venous leg ulcers. J Wound Care. 2002;11:335-341.
71.
VevesASheehanPPhamHT. A randomized, controlled trial of Promogran (a collagen/oxidized regenerated cellulose dressing) vs standard treatment in the management of diabetic foot ulcers. Arch Surg. 2002;137:822-827.
72.
GhatnekarOWillisMPerssonU. Cost-effectiveness of treating deep diabetic foot ulcers with Promogran in four European countries. J Wound Care. 2002;11:70-74.
73.
SchmutzJLMeaumeSFaysS. Evaluation of the nano-oligosaccharide factor lipido-colloid matrix in the local management of venous leg ulcers: results of a randomised, controlled trial. Int Wound J. 2008;5:172-182.
74.
GentzkowGDIwasakiSDHershonKS. Use of Dermagraft, a cultured human dermis, to treat diabetic foot ulcers. Diabetes Care. 1996;19:350-354.
75.
HanftJRSurprenantMS. Healing of chronic foot ulcers in diabetic patients treated with a human fibroblast-derived dermis. J Foot Ankle Surg. 2002;41:291-299.
76.
OmarAAMavorAI.DJonesAMHomer-VanniasinkamS. Treatment of venous leg ulcers with Dermagraft®. Eur J Vasc Endovasc Surg. 2004;27:666-672.
77.
HardingKSumnerMCardinalM. A prospective, multicentre, randomised controlled study of human fibroblast-derived dermal substitute (Dermagraft) in patients with venous leg ulcers. Int Wound J. 2013;10:132-137.
78.
KrishnamoorthyLHardingKGriffithsD. The clinical and histological effects of Dermagraft® in the healing of chronic venous leg ulcers. Phlebology. 2003;18:12-22.
79.
NaughtonGMansbridgeJGentzkowG. A metabolically active human dermal replacement for the treatment of diabetic foot ulcers. Artificial Organs. 1997;21:1203-1210.
80.
ZelenCMSerenaTEDenoziereGFetterolfDE. A prospective randomised comparative parallel study of amniotic membrane wound graft in the management of diabetic foot ulcers. Int Wound J. 2013;10:502-507.
81.
EdmondsM. Apligraf in the treatment of neuropathic diabetic foot ulcers. Int J Lower Extremity Wounds. 2009;8:11-18.
82.
FalangaVSabolinskiM. A bilayered living skin construct (APLIGRAF) accelerates complete closure of hard-to-heal venous ulcers. Wound Repair Regen. 1999;7:201-207.
83.
FalangaVMargolisDAlvarezO. Rapid healing of venous ulcers and lack of clinical rejection with an allogeneic cultured human skin equivalent. Human Skin Equivalent Investigators Group. Arch Dermatol. 1998;134:293-300.
84.
VevesAFalangaVArmstrongDGSabolinskiML. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinical trial. Diabetes Care. 2001;24:290-295.
